These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30526220)

  • 1. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
    Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
    Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alectinib for advanced
    Ly AC; Olin JL; Smith MB
    Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Gadotti LL; Nogueira Amorim Canedo FS; Ribeiro MFSA; Sacardo KP; Saddi R; Machado Alessi JV; de Abreu Testagrossa L; Katz A
    Clin Lung Cancer; 2021 May; 22(3):e481-e486. PubMed ID: 32771343
    [No Abstract]   [Full Text] [Related]  

  • 7. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
    Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
    Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
    Ikeda S; Yoshioka H; Arita M; Sakai T; Sone N; Nishiyama A; Niwa T; Hotta M; Tanaka T; Ishida T
    Jpn J Clin Oncol; 2015 Feb; 45(2):221-4. PubMed ID: 25398579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
    Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
    Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM; Noonan S; O'Bryant C; Jimeno A
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
    Kaira K; Naruse I; Shimizu K; Asao T
    J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
    Tomasini P; Egea J; Souquet-Bressand M; Greillier L; Barlesi F
    Ther Adv Respir Dis; 2019; 13():1753466619831906. PubMed ID: 30786826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
    J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
    Ning S; Shi C; Zhang H; Li J
    Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
    Lim CA; Banyi N; Tucker T; Ionescu DN; Melosky B
    Curr Oncol; 2022 Feb; 29(2):848-852. PubMed ID: 35200571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.